GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Mylan Laboratories, Inc. (MYL) [hlAlert]

Rating:
Buy MYL
up 120.60 %

Mylan Laboratories, Inc. (MYL) rated Buy with price target $42 by Argus

Posted on: Thursday,  Aug 8, 2013  3:25 PM ET by Argus

Argus rated Buy Mylan Laboratories, Inc. (NASDAQ: MYL) on 08/08/2013. Previously Argus rated Buy Mylan Laboratories, Inc. (NASDAQ: MYL) on 05/24/2011.,
when the stock price was $23.34. Since then, Mylan Laboratories, Inc. has gained 120.61% as of 12/03/2015's recent price of $51.49.
If you would have followed the previous Argus's recommendation on MYL, you would have gained 120.6% of your investment in 1654 days.

Mylan Inc. (Mylan) and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients (API). As of May 5, 2009, the Company held a 71.2% interest in Matrix Laboratories Limited (Matrix). Through Matrix, it manufactures and supplies API for its own products and pipeline, as well as for third parties. Mylan has three segments: the Generics Segment, the Matrix Segment and the Specialty Segment. Mylan markets more than 570 products to consumers in more than 140 countries. Mylan?s products cover an array of therapeutic categories, and offer a range of dosage forms and delivery systems, including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. On June 2, 2008, the Company acquired Merck KGaA?s Central & Eastern Europe (CEE) generics businesses.

Argus Research is an independent research firm, and our business is producing, distributing and marketing high-quality investment and economic research. Our recommendations - BUY, HOLD and SELL - reflect the judgment of an analyst about a company's prospects as an investment in terms of value, expected growth and risks. Argus Research does not bring companies public, advise companies on mergers and acquisitions, broker trades, make markets in stocks or manage money. Our independence allows us to make critical judgments about companies that we might not be so free to make were we competing for a firm's underwriting business. Because we're not a broker/dealer, we don't have "inventory" of a stock that we have to move with a tainted recommendation. We have developed a six-point system for analyzing the stocks in our Universe of Coverage. We believe that this system
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/8/2013 3:25 PM Buy
None
37.07 42.00
as of 12/13/2013
1 Week down  -5.34 %
1 Month up  0.38 %
3 Months up  7.34 %
1 YTD up  52.20 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/4/2013 8:25 AM Buy
None
29.90 35.00
5/24/2011 9:25 AM Buy
None
23.34 29.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy